Targeting C3a and C5a Signaling-A Game Changer for Cancer Therapy?

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• The complement system traditionally viewed as tumor-suppressive, is now recognized to promote cancer progression within the tumor microenvironment (TME).
• Anaphylatoxins C3a and C5a are implicated as key drivers of tumor growth, angiogenesis, and metastasis.
• Their interaction with immune cells in the TME, such as tumor-associated macrophages (TAMs), fosters an immunosuppressive environment.

Purpose of the Study:

• To systematically review studies on complement system activation in the TME.
• To elucidate the role of C3a and C5a signaling pathways in cancer progression and TME interactions.
• To evaluate the therapeutic potential of targeting these pathways for anti-cancer immunity.

Main Methods:

• Systematic literature review.
• Analysis of studies investigating complement activation markers (C3a, C5a) in various cancers.
• Review of research on the effects of C3a and C5a on TME components and tumor behavior.

Main Results:

• Evidence indicates C3a and C5a signaling promotes tumor proliferation, angiogenesis, and metastasis.
• These anaphylatoxins modulate immune cells within the TME, leading to immunosuppression.
• Targeting C3a and C5a pathways demonstrates potential in inhibiting tumor growth and metastasis.

Conclusions:

• The complement system's role in cancer is complex, with C3a and C5a acting as pro-tumorigenic factors in the TME.
• Targeting C3a and C5a signaling pathways represents a promising therapeutic strategy to enhance anti-tumor immune responses.
• Further research is warranted to fully understand and exploit the therapeutic potential of complement inhibition in oncology.